🔎 Trials Near Me

Почетна › Беркитов лимфом › Јута

Kliničke studije za Беркитов лимфом u državi Јута

7 studija za Беркитов лимфом traži učesnike na lokacijama u državi Јута.

Gradovi u državi Јута

Zvanični tekst studije (na engleskom)

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

  • Primary Children's Hospital, Salt Lake City
Тражи се учесникФаза 1
Узраст од 0 до 18 · Оба пола · Ажурирано 13. 11. 2026. · NCT06173518

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • Primary Children's Hospital, Salt Lake City
Тражи се учесникФаза 2
Узраст од 1 до 30 · Оба пола · Ажурирано 12. 11. 2026. · NCT04546399

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

  • Huntsman Cancer Institute/University of Utah, Salt Lake City
Тражи се учесникФаза 3
Узраст од 18 до 39 · Оба пола · Ажурирано 3. 11. 2026. · NCT03150693

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  • Intermountain - Primary Children's Hospital ( Site 1014), Salt Lake City
Тражи се учесникФаза 1/2
6 Months – 25 Years · Оба пола · Ажурирано 30. 10. 2026. · NCT06395103

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Primary Children's Hospital, Salt Lake City
Тражи се учесникФаза 3
365 Days – 25 Years · Оба пола · Ажурирано 25. 8. 2026. · NCT03959085

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

  • Primary Children's Hospital, Salt Lake City
Тражи се учесникФаза 2
Узраст од 7 до 25 · Оба пола · Ажурирано 19. 8. 2026. · NCT05082519

Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.